The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).
A. Finelli
No relevant relationships to disclose
A. M. Horgan
No relevant relationships to disclose
A. Evans
No relevant relationships to disclose
T. K. Kim
No relevant relationships to disclose
K. Durrant
No relevant relationships to disclose
S. Yap
No relevant relationships to disclose
C. A. Cassol
No relevant relationships to disclose
W. Dubinski
No relevant relationships to disclose
N. Fleshner
No relevant relationships to disclose
M. A. S. Jewett
No relevant relationships to disclose
A. M. Joshua
No relevant relationships to disclose
S. S. Sridhar
No relevant relationships to disclose
A. Zlotta
No relevant relationships to disclose
J. J. Knox
No relevant relationships to disclose